Inactive Instrument

UMN Pharma Inc.

4585

JP3944320005

Biotechnology & Medical Research

UMN Pharma Inc. announced that it has received ¥1.639 billion in funding from Shionogi & Co., Ltd.

November 15, 2017

On November 16, 2017, UMN Pharma Inc. (TSE:4585) closed the transaction.

Latest news about UMN Pharma Inc.

AIM ImmunoTech Inc. Enters into Mutual Confidentiality Agreement with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd	27/04/20	CI
Shionogi & Co., Ltd. completed the acquisition of 52.74% stake in UMN Pharma Inc. for ¥5 billion.	11/12/19	CI
Shionogi & Co., Ltd. made a tender offer to acquire 69.6% stake in UMN Pharma Inc for approximately ¥6.7 billion.	29/10/19	CI
UMN Pharma Inc. Reports Non-Consolidated Earnings Results for the Six Months Ended June 30, 2019; Provides Earnings Guidance for the Fiscal Year Ending December 31, 2019	30/07/19	CI
UMN Pharma Inc. Reports Non-Consolidated Earnings Results for the Quarter Ended March 31, 2018; Provides Earnings Guidance for the Fiscal Year Ending December 31, 2018	26/04/18	CI
UMN Pharma Inc. Announces Non Consolidated Earnings Results for the Year Ended December 31, 2017; Provides Earnings Guidance for the Full Year of 2018	13/02/18	CI
UMN Pharma Inc. announced that it has received ¥1.639 billion in funding from Shionogi & Co., Ltd.	15/11/17	CI
UMN Pharma Inc. announced that it expects to receive ¥1.64 billion in funding from Shionogi & Co., Ltd.	30/10/17	CI
Umn Pharma Inc. Announces Non-Consolidated Earnings Results for the Nine Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending December. 31, 2017	30/10/17	CI
UMN Pharma Inc.(TSE:4585) dropped from S&P Global BMI Index	18/09/17	CI
UMN Pharma Inc. Announces Nonconsolidated Earnings Results for the Six Months Ended June 30, 2017; Provides Nonconsolidated Earnings Guidance for the Year Ending December 31, 2017	30/07/17	CI
Umn Pharma Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provide Earnings Guidance for the Year 2017	27/04/17	CI
UMN Pharma Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2016; Provides Earnings Guidance for the Year Ending December 31, 2017	13/02/17	CI
API Co., Ltd. acquired 50% stake in Unigen KK from UMN Pharma Inc..	31/01/17	CI
Umn Pharma Inc. Announces Consolidated Earnings Results for the First Nine Months Ended September 30, 2016; Provides Earnings Guidance for the Year Ending March 31, 2016	30/10/16	CI
UMN Pharma Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2016; Provides Earnings Guidance for the Year Ending December 31, 2016	28/07/16	CI
UMN Pharma Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2016	27/04/16	CI
UMN Pharma Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2015	11/02/16	CI
UMN Pharma Inc. Announces Consolidated Earnings Results for the First Nine Month Ended September 30, 2015; Updates Consolidated Earnings Guidance for the Year Ending March 31, 2016	29/10/15	CI
UMN Pharma Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year Ending December 31, 2015	30/07/15	CI
UMN Pharma Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year Ending December 31, 2015	29/04/15	CI
UMN Pharma Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year Ending December 31, 2015	12/02/15	CI
Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation Enter into Agreement to Evaluate Sourcing Flublok® from Japan	22/12/14	CI
UMN Pharma Inc. Reports Consolidated Earnings Results for the First Half Ended June 30, 2014; Provides Earnings Forecast for the Year Ending December 31, 2014, 2015, 2016 and 2017	30/07/14	CI
Daiichi Sankyo and UMN Pharma to Collaborate on Norovirus Vaccine	16/02/14	CI

UMN Pharma Inc. is a Japan-based biotechnology company mainly engaged in the biopharmaceuticals development business. The Company is engaged in the development, manufacturing and sales of biopharmaceuticals based on the baculovirus expression vector system (BEVS) manufacturing platform. The Company's pipelines include seasonal influenza vaccine UMN-0502, pandemic influenza vaccine UMN-0501, pandemic influenza vaccine UMN-0901 and norovirus/rotavirus vaccine UMN-2003.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-2.21%	21.28B
GENMAB A/S	-5.48%	18.8B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B

Bio Therapeutic Drugs

UMN Pharma Inc.

Equities

4585

JP3944320005

Biotechnology & Medical Research

UMN Pharma Inc. announced that it has received ¥1.639 billion in funding from Shionogi & Co., Ltd.

Latest news about UMN Pharma Inc.

Chart UMN Pharma Inc.

Company Profile

Sector Bio Therapeutic Drugs